Skip to content

A prospective study of safety and efficacy of Novel Coronavirus vaccine in patients with maintenance hemodialysis and peritoneal dialysis

A prospective study of safety and efficacy of Novel Coronavirus vaccine in patients with maintenance hemodialysis and peritoneal dialysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100050234
Enrollment
Unknown
Registered
2021-08-24
Start date
2021-10-01
Completion date
Unknown
Last updated
2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage renal disease

Interventions

Maintenance hemodialysis group:Nil
Peritoneal dialysis group:Nil

Sponsors

The Third People's Hospital of Chengdu
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Hemodialysis and peritoneal dialysis patients were maintained in a stable condition; 2. Aged>=18 years; 3. Hypertension was stable under medication control, with blood pressure <160/100mmHg; 4. Fasting blood glucose <=13.9mmol/L; 5. Volunteer to receive COVID-19 inactivated vaccine.

Exclusion criteria

Exclusion criteria: 1. Allergic to the ingredients of the vaccine; 2. Patients with previous severe allergic reactions to vaccines (such as acute allergic reactions, angoneurotic edema, dyspnea, etc.); 3. People with uncontrolled epilepsy and other serious neurological diseases (e.g., transverse myelitis, Guillain-Barre syndrome, demyelinating disease, etc.); 4. People who are having a fever, or have an acute illness, or the acute phase of a chronic disease, or a serious chronic disease that has not been controlled; 5. Pregnant woman.

Design outcomes

Primary

MeasureTime frame
Novel coronavirus neutralizing antibodies;Local adverse reactions to vaccine injection;Systemic adverse reactions after vaccination;

Countries

China

Contacts

Public ContactShu Ying

The Third People's Hospital of Chengdu

383493787@qq.com+86 13808185894

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026